Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronger conviction, whereas Merck and Pfizer were rated Neutral despite raised targets. The firm highlighted differing growth prospects, with Lilly and AbbVie showing robust revenue growth and promising drug momentum, while Merck and Pfizer face more uncertainty and upcoming catalysts. Investors should watch clinical results and 2027 earnings revisions for clearer direction.
As of Oct 09, 2026 18:51 WIB, Eli Lilly trades at USD 1,168.00 with a slight 1-day decline of 0.16% on Pluang. AbbVie shows a modest 0.20% gain, priced at USD 272.97, with a strong buy interest of 78% among Pluang users. Merck, meanwhile, faces heavier selling pressure with 82% sell activity despite a small 0.13% price increase to USD 142.58.
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
